SlideShare a Scribd company logo
 Superior vena cava (SVC) syndrome results
from any condition that leads to obstruction
of blood flow through the SVC.
 Obstruction can be caused by invasion or
external compression of the superior vena
cava by adjacent pathologic processes
involving the right lung, lymph nodes, and
other mediastinal structures, or by
thrombosis of blood within the SVC.
 In some cases, both external compression
and thrombosis coexist
 In the preantibiotic era, syphilitic thoracic
aortic aneurysms, fibrosing mediastinitis, and
other complications of untreated infection
were frequent causes of the SVC syndrome.
 In the postantibiotic era, malignancy became
the most common cause.
 More recently, the incidence of SVC
syndrome due to thrombosis has risen,
largely because of increased use of
intravascular devices such as catheters and
pacemaker wires.
PATHOPHYSIOLOGY —
 Obstruction of the SVC can be caused by
invasion or external compression by adjacent
pathologic processes involving the right lung,
lymph nodes, or other mediastinal
structures, or by thrombosis of blood within
the SVC.
 As the flow of blood within the SVC becomes
obstructed, venous collaterals form,
establishing alternative pathways for the
return of venous blood to the right atrium.
 Collateral veins may arise from the azygos,
internal mammary, lateral thoracic,
paraspinous, and esophageal venous systems.
 The venous collaterals dilate over several
weeks.
 As a result, upper body venous pressure is
markedly elevated initially but decreases
over time.
 However, even when well-developed
collateral drainage patterns are present,
central venous pressures remain elevated,
producing the characteristic signs and
symptoms of SVC syndrome.
 The rapidity of onset of symptoms and signs
from SVC obstruction depends upon the rate
at which complete obstruction of the SVC
occurs in relation to the recruitment of
venous collaterals.
 Patients with malignant disease may develop
symptoms of SVC syndrome within weeks to
months because rapid tumor growth does not
allow adequate time to develop collateral
flow.
 The interstitial edema of the head and neck
is visually striking but generally of little
clinical consequence.
 However, edema may narrow the lumen of
the nasal passages and larynx, potentially
compromising the function of the larynx or
pharynx and causing dyspnea, stridor, cough,
hoarseness, and dysphagia.
 In addition, cerebral edema can also occur
and lead to cerebral ischemia, herniation,
and possibly death.
 Cardiac output may be diminished transiently
by acute SVC obstruction, but within a few
hours, blood return is reestablished by
increased venous pressure and collaterals.
 Hemodynamic compromise, if present, more
often results from mass effect on the heart
than from SVC compression
 Etiology :
 Malignancy —
 An intrathoracic malignancy is responsible
for 60 to 85 percent of cases of SVC
syndrome.
 Non-small cell lung cancer (NSCLC) is the
most common malignant cause of SVC
syndrome, accounting for 50 percent of all
cases , followed by small cell lung cancer
(SCLC, 25 percent of all cases) and non-
Hodgkin lymphoma (NHL, 10 percent of
cases).
 Together, lung cancer and NHL are
responsible for approximately 95 percent of
cases of SVC syndrome that are caused by
malignancy .
 Lung cancer —
 Approximately 2 to 4 percent of patients with lung
cancer develop SVC syndrome at some point during
their disease course .
 SVC syndrome is more common with SCLC, occurring
in approximately 10 percent of cases at presentation.
 This is presumably because SCLC develops and grows
rapidly in central rather than peripheral airways.
 Fewer than 2 percent of patients presenting with
NSCLC have SVC syndrome as a complication, but
because of the higher incidence, NSCLC is a more
frequent cause of SVC syndrome than is SCLC .
 Venous obstruction in these cases results from
extrinsic compression of the SVC by either the
primary tumor or enlarged mediastinal lymph nodes,
or as a result of direct tumor invasion of the SVC .
 Lymphoma —
 SVC syndrome develops in 2 to 4 percent of
cases of NHL.
 Diffuse large cell and lymphoblastic
lymphomas are the most common subtypes
that are associated with SVC syndrome.
 SVC syndrome is even more common in
patients with primary mediastinal large B-
cell lymphoma with sclerosis, an unusual and
aggressive NHL subtype that represents 3 to 7
percent of all diffuse large-cell lymphomas.
 Patients typically present with a rapidly
enlarging anterior mediastinal mass,
frequently with associated SVC syndrome.
 Although most NHLs cause SVC syndrome by
extrinsic compression due to enlarged lymph
nodes , patients with intravascular
(angiotropic) lymphoma have intravascular
occlusion as the primary pathogenic
mechanism .
 Other — Other malignant tumors that are
less commonly associated with the SVC
syndrome include : thymoma, primary
mediastinal germ cell neoplasms,
mesothelioma, and solid tumors with
mediastinal lymph node metastases (eg,
breast cancer)
 Nonmalignant disorders —
 Nonmalignant conditions account for 15 to
40 percent of SVC obstructions.
 Although the incidence of SVC syndrome due
to infections such as tuberculosis and syphilis
has decreased, there has been an increase in
SVC thrombosis associated with the presence
of intravascular devices such as central
venous catheters and cardiac pacemaker
leads
 Clinical maniestations:
 Regardless of etiology, dyspnea is the
most common symptom .
 In addition, patients frequently complain
of facial swelling or head fullness, which
may be exacerbated by bending forward
or lying down.
 Other symptoms include arm swelling,
cough, chest pain, or dysphagia.
 Patients with cerebral edema may have
headaches, confusion, or possibly coma.
 On physical examination, the most common
findings are facial edema and venous distension
in the neck and on the chest wall .
 Arm edema, cyanosis, and facial plethora can be
seen.
 In most cases, symptoms are gradually
progressive over several weeks and then get
better over time, due to the development of
venous collaterals.

More Related Content

What's hot

Head and Neck Cancer
Head and Neck Cancer Head and Neck Cancer
Head and Neck Cancer saimedical
 
Non Hodgkin's Lymphoma
Non Hodgkin's LymphomaNon Hodgkin's Lymphoma
Non Hodgkin's Lymphoma
trial4neha
 
MANAGEMENT OF MENINGIOMA
MANAGEMENT OF MENINGIOMAMANAGEMENT OF MENINGIOMA
MANAGEMENT OF MENINGIOMA
Kanhu Charan
 
Non Small Cell Lung Cancer
Non Small Cell Lung CancerNon Small Cell Lung Cancer
Non Small Cell Lung Cancerfondas vakalis
 
Ca Nasopharynx contouring.pptx
Ca Nasopharynx contouring.pptxCa Nasopharynx contouring.pptx
Ca Nasopharynx contouring.pptx
Sayan Das
 
Quantec dr. upasna saxena (2)
Quantec   dr. upasna saxena (2)Quantec   dr. upasna saxena (2)
Quantec dr. upasna saxena (2)
Upasna Saxena
 
Radiotherapy lymphoma
Radiotherapy lymphoma Radiotherapy lymphoma
Radiotherapy lymphoma
vrinda singla
 
Principles of Medical Oncology
Principles of Medical OncologyPrinciples of Medical Oncology
Principles of Medical Oncology
Eneutron
 
Principles of radiotherapy in gastric carcinoma
Principles of radiotherapy in gastric carcinomaPrinciples of radiotherapy in gastric carcinoma
Principles of radiotherapy in gastric carcinoma
Anil Gupta
 
Management of carcinomas of urinary bladder
Management of carcinomas of urinary bladderManagement of carcinomas of urinary bladder
Management of carcinomas of urinary bladder
Shashank Bansal
 
Principles of medical_oncology dr. varun
Principles of medical_oncology  dr. varunPrinciples of medical_oncology  dr. varun
Principles of medical_oncology dr. varunVarun Goel
 
Hodgkins lymphoma
Hodgkins lymphomaHodgkins lymphoma
Hodgkins lymphoma
Parneet Singh
 
Treatment of Cancer of the Esophagus
Treatment of Cancer of the EsophagusTreatment of Cancer of the Esophagus
Treatment of Cancer of the Esophagus
Robert J Miller MD
 
TARGET DELINEATION OF CANCER ESOPHAGUS
TARGET DELINEATION OF CANCER ESOPHAGUSTARGET DELINEATION OF CANCER ESOPHAGUS
TARGET DELINEATION OF CANCER ESOPHAGUS
Kanhu Charan
 
Brain metastasis
Brain metastasis Brain metastasis
Brain metastasis
Kiran Ramakrishna
 
Hodgkins lymphoma treat
Hodgkins lymphoma treatHodgkins lymphoma treat
Hodgkins lymphoma treat
LAKSHMI DEEPTHI GEDELA
 
Prostate ca
Prostate caProstate ca
Contouring in breast cancer current practice and future directions
Contouring in breast cancer current practice and future directions Contouring in breast cancer current practice and future directions
Contouring in breast cancer current practice and future directions
Anil Gupta
 

What's hot (20)

Head and Neck Cancer
Head and Neck Cancer Head and Neck Cancer
Head and Neck Cancer
 
Non Hodgkin's Lymphoma
Non Hodgkin's LymphomaNon Hodgkin's Lymphoma
Non Hodgkin's Lymphoma
 
MANAGEMENT OF MENINGIOMA
MANAGEMENT OF MENINGIOMAMANAGEMENT OF MENINGIOMA
MANAGEMENT OF MENINGIOMA
 
Non Small Cell Lung Cancer
Non Small Cell Lung CancerNon Small Cell Lung Cancer
Non Small Cell Lung Cancer
 
Ca Nasopharynx contouring.pptx
Ca Nasopharynx contouring.pptxCa Nasopharynx contouring.pptx
Ca Nasopharynx contouring.pptx
 
Quantec dr. upasna saxena (2)
Quantec   dr. upasna saxena (2)Quantec   dr. upasna saxena (2)
Quantec dr. upasna saxena (2)
 
Radiotherapy lymphoma
Radiotherapy lymphoma Radiotherapy lymphoma
Radiotherapy lymphoma
 
Principles of Medical Oncology
Principles of Medical OncologyPrinciples of Medical Oncology
Principles of Medical Oncology
 
Principles of radiotherapy in gastric carcinoma
Principles of radiotherapy in gastric carcinomaPrinciples of radiotherapy in gastric carcinoma
Principles of radiotherapy in gastric carcinoma
 
Management of carcinomas of urinary bladder
Management of carcinomas of urinary bladderManagement of carcinomas of urinary bladder
Management of carcinomas of urinary bladder
 
Principles of medical_oncology dr. varun
Principles of medical_oncology  dr. varunPrinciples of medical_oncology  dr. varun
Principles of medical_oncology dr. varun
 
Radiation therapy in wilms tumour
Radiation therapy in wilms tumourRadiation therapy in wilms tumour
Radiation therapy in wilms tumour
 
Hodgkins lymphoma
Hodgkins lymphomaHodgkins lymphoma
Hodgkins lymphoma
 
Treatment of Cancer of the Esophagus
Treatment of Cancer of the EsophagusTreatment of Cancer of the Esophagus
Treatment of Cancer of the Esophagus
 
TARGET DELINEATION OF CANCER ESOPHAGUS
TARGET DELINEATION OF CANCER ESOPHAGUSTARGET DELINEATION OF CANCER ESOPHAGUS
TARGET DELINEATION OF CANCER ESOPHAGUS
 
Medulloblastomas
MedulloblastomasMedulloblastomas
Medulloblastomas
 
Brain metastasis
Brain metastasis Brain metastasis
Brain metastasis
 
Hodgkins lymphoma treat
Hodgkins lymphoma treatHodgkins lymphoma treat
Hodgkins lymphoma treat
 
Prostate ca
Prostate caProstate ca
Prostate ca
 
Contouring in breast cancer current practice and future directions
Contouring in breast cancer current practice and future directions Contouring in breast cancer current practice and future directions
Contouring in breast cancer current practice and future directions
 

Similar to Chapter 37 svco

Superior Vena Cava Syndrome. Etiology and management
Superior Vena Cava Syndrome. Etiology and managementSuperior Vena Cava Syndrome. Etiology and management
Superior Vena Cava Syndrome. Etiology and management
RomanusMapunda1
 
Superior vena cava syndrome
Superior vena cava syndromeSuperior vena cava syndrome
Superior vena cava syndrome
rod prasad
 
SVCS.pptx
SVCS.pptxSVCS.pptx
SVCS.pptx
AnandHosalli
 
Superior vena cava syndrome
Superior vena cava syndromeSuperior vena cava syndrome
Superior vena cava syndrome
Amit Jose
 
SVCS.pptx
SVCS.pptxSVCS.pptx
Cardiac tumours
Cardiac tumoursCardiac tumours
Cardiac tumours
Ankur Batra
 
Extra pulmonary TB
Extra pulmonary TBExtra pulmonary TB
Extra pulmonary TB
DR.SHARIF AHSAN
 
Endocarditis presentation to internal medicine2019
Endocarditis presentation to internal medicine2019Endocarditis presentation to internal medicine2019
Endocarditis presentation to internal medicine2019
hospital
 
Superior vena cava syndrome
Superior vena cava syndromeSuperior vena cava syndrome
Superior vena cava syndrome
Sreekanth Nallam
 
SVC syndrome - a surgical perspective
SVC syndrome - a surgical perspectiveSVC syndrome - a surgical perspective
SVC syndrome - a surgical perspective
SrikanthK120
 
Cerebral Venous Sinus Thrombosis (CVST): Causes, Risks, Complications, Diag...
Cerebral Venous Sinus Thrombosis (CVST): Causes,   Risks, Complications, Diag...Cerebral Venous Sinus Thrombosis (CVST): Causes,   Risks, Complications, Diag...
Cerebral Venous Sinus Thrombosis (CVST): Causes, Risks, Complications, Diag...
Lazoi Lifecare Private Limited
 
Pulmonary embolism ms
Pulmonary embolism msPulmonary embolism ms
Pulmonary embolism mscardilogy
 
Acyanotic chd
Acyanotic chdAcyanotic chd
Acyanotic chd
Hristo Rahman
 
Bindhya dvt
Bindhya dvtBindhya dvt
Bindhya dvt
bindhyanidhin
 
Cerebrovascular diseases.pptx
Cerebrovascular diseases.pptxCerebrovascular diseases.pptx
Cerebrovascular diseases.pptx
tesa10
 
Acute Chest Syndrome (ACS) in Sickle Cell Disease.
Acute Chest Syndrome (ACS) in Sickle Cell Disease.Acute Chest Syndrome (ACS) in Sickle Cell Disease.
Acute Chest Syndrome (ACS) in Sickle Cell Disease.
Abdulmumini Shehu, B.Pharm, MD.
 
Final superior vena cava syndrome .pptx
Final superior vena cava syndrome .pptxFinal superior vena cava syndrome .pptx
Final superior vena cava syndrome .pptx
KhadiraMohammed
 
Aortic stenosis 11 4
Aortic stenosis 11 4Aortic stenosis 11 4
Aortic stenosis 11 4
azza mokhtar
 
Thrombosis of major veins.
Thrombosis of major veins.Thrombosis of major veins.
Thrombosis of major veins.
Dr-Ahmed Mohammed
 

Similar to Chapter 37 svco (20)

Superior Vena Cava Syndrome. Etiology and management
Superior Vena Cava Syndrome. Etiology and managementSuperior Vena Cava Syndrome. Etiology and management
Superior Vena Cava Syndrome. Etiology and management
 
Superior vena cava syndrome
Superior vena cava syndromeSuperior vena cava syndrome
Superior vena cava syndrome
 
SVCS.pptx
SVCS.pptxSVCS.pptx
SVCS.pptx
 
Superior vena cava syndrome
Superior vena cava syndromeSuperior vena cava syndrome
Superior vena cava syndrome
 
SVCS.pptx
SVCS.pptxSVCS.pptx
SVCS.pptx
 
Cardiac tumours
Cardiac tumoursCardiac tumours
Cardiac tumours
 
Extra pulmonary TB
Extra pulmonary TBExtra pulmonary TB
Extra pulmonary TB
 
Endocarditis presentation to internal medicine2019
Endocarditis presentation to internal medicine2019Endocarditis presentation to internal medicine2019
Endocarditis presentation to internal medicine2019
 
Superior vena cava syndrome
Superior vena cava syndromeSuperior vena cava syndrome
Superior vena cava syndrome
 
SVC syndrome - a surgical perspective
SVC syndrome - a surgical perspectiveSVC syndrome - a surgical perspective
SVC syndrome - a surgical perspective
 
Cerebral Venous Sinus Thrombosis (CVST): Causes, Risks, Complications, Diag...
Cerebral Venous Sinus Thrombosis (CVST): Causes,   Risks, Complications, Diag...Cerebral Venous Sinus Thrombosis (CVST): Causes,   Risks, Complications, Diag...
Cerebral Venous Sinus Thrombosis (CVST): Causes, Risks, Complications, Diag...
 
Pulmonary embolism ms
Pulmonary embolism msPulmonary embolism ms
Pulmonary embolism ms
 
Acyanotic chd
Acyanotic chdAcyanotic chd
Acyanotic chd
 
Bindhya dvt
Bindhya dvtBindhya dvt
Bindhya dvt
 
Cerebrovascular diseases.pptx
Cerebrovascular diseases.pptxCerebrovascular diseases.pptx
Cerebrovascular diseases.pptx
 
Dvt
Dvt Dvt
Dvt
 
Acute Chest Syndrome (ACS) in Sickle Cell Disease.
Acute Chest Syndrome (ACS) in Sickle Cell Disease.Acute Chest Syndrome (ACS) in Sickle Cell Disease.
Acute Chest Syndrome (ACS) in Sickle Cell Disease.
 
Final superior vena cava syndrome .pptx
Final superior vena cava syndrome .pptxFinal superior vena cava syndrome .pptx
Final superior vena cava syndrome .pptx
 
Aortic stenosis 11 4
Aortic stenosis 11 4Aortic stenosis 11 4
Aortic stenosis 11 4
 
Thrombosis of major veins.
Thrombosis of major veins.Thrombosis of major veins.
Thrombosis of major veins.
 

More from Nilesh Kucha

Chapter 39 role of radiotherapy in benign diseases.pptx [read only]
Chapter 39 role of radiotherapy in benign diseases.pptx [read only]Chapter 39 role of radiotherapy in benign diseases.pptx [read only]
Chapter 39 role of radiotherapy in benign diseases.pptx [read only]
Nilesh Kucha
 
Chapter 39 role of radiotherapy in benign diseases
Chapter 39 role of radiotherapy in benign diseasesChapter 39 role of radiotherapy in benign diseases
Chapter 39 role of radiotherapy in benign diseases
Nilesh Kucha
 
Chapter 39 role of radiotherapy in benign diseases
Chapter 39 role of radiotherapy in benign diseasesChapter 39 role of radiotherapy in benign diseases
Chapter 39 role of radiotherapy in benign diseases
Nilesh Kucha
 
Chapter 38 role of surgery in cancer prevention
Chapter 38 role of surgery in cancer preventionChapter 38 role of surgery in cancer prevention
Chapter 38 role of surgery in cancer prevention
Nilesh Kucha
 
Chapter 36 t reg cells
Chapter 36 t reg cellsChapter 36 t reg cells
Chapter 36 t reg cells
Nilesh Kucha
 
Chapter 35 tumor lysis syndrome
Chapter 35 tumor lysis syndromeChapter 35 tumor lysis syndrome
Chapter 35 tumor lysis syndrome
Nilesh Kucha
 
Chapter 34 medical stat
Chapter 34 medical statChapter 34 medical stat
Chapter 34 medical stat
Nilesh Kucha
 
Chapter 33 isolated tumor cells
Chapter 33 isolated tumor cellsChapter 33 isolated tumor cells
Chapter 33 isolated tumor cells
Nilesh Kucha
 
Chapter 32 invasion and metastasis
Chapter 32 invasion and metastasisChapter 32 invasion and metastasis
Chapter 32 invasion and metastasis
Nilesh Kucha
 
Chapter 31 genetic counselling
Chapter 31 genetic counsellingChapter 31 genetic counselling
Chapter 31 genetic counselling
Nilesh Kucha
 
Chapter 30 febrile neutropenia
Chapter 30 febrile neutropeniaChapter 30 febrile neutropenia
Chapter 30 febrile neutropenia
Nilesh Kucha
 
Chapter 29 dendritic cells
Chapter 29 dendritic cellsChapter 29 dendritic cells
Chapter 29 dendritic cells
Nilesh Kucha
 
Chapter 28 clincal trials
Chapter 28 clincal trials Chapter 28 clincal trials
Chapter 28 clincal trials
Nilesh Kucha
 
Chapter 27 chemotherapy side effects dr lms
Chapter 27 chemotherapy side effects  dr lmsChapter 27 chemotherapy side effects  dr lms
Chapter 27 chemotherapy side effects dr lms
Nilesh Kucha
 
Chapter 26 chemoprevention of cancer
Chapter 26 chemoprevention of cancerChapter 26 chemoprevention of cancer
Chapter 26 chemoprevention of cancer
Nilesh Kucha
 
Chapter 25 assessment of clincal responses
Chapter 25 assessment of clincal responsesChapter 25 assessment of clincal responses
Chapter 25 assessment of clincal responses
Nilesh Kucha
 
Chapter 24.3 metronomic chemotherapy
Chapter 24.3 metronomic chemotherapyChapter 24.3 metronomic chemotherapy
Chapter 24.3 metronomic chemotherapy
Nilesh Kucha
 
Chapter 24.2 lmwh in cancer asso thrombosis
Chapter 24.2 lmwh in cancer asso thrombosisChapter 24.2 lmwh in cancer asso thrombosis
Chapter 24.2 lmwh in cancer asso thrombosis
Nilesh Kucha
 
Chapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodiesChapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodies
Nilesh Kucha
 
Chapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitorsChapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitors
Nilesh Kucha
 

More from Nilesh Kucha (20)

Chapter 39 role of radiotherapy in benign diseases.pptx [read only]
Chapter 39 role of radiotherapy in benign diseases.pptx [read only]Chapter 39 role of radiotherapy in benign diseases.pptx [read only]
Chapter 39 role of radiotherapy in benign diseases.pptx [read only]
 
Chapter 39 role of radiotherapy in benign diseases
Chapter 39 role of radiotherapy in benign diseasesChapter 39 role of radiotherapy in benign diseases
Chapter 39 role of radiotherapy in benign diseases
 
Chapter 39 role of radiotherapy in benign diseases
Chapter 39 role of radiotherapy in benign diseasesChapter 39 role of radiotherapy in benign diseases
Chapter 39 role of radiotherapy in benign diseases
 
Chapter 38 role of surgery in cancer prevention
Chapter 38 role of surgery in cancer preventionChapter 38 role of surgery in cancer prevention
Chapter 38 role of surgery in cancer prevention
 
Chapter 36 t reg cells
Chapter 36 t reg cellsChapter 36 t reg cells
Chapter 36 t reg cells
 
Chapter 35 tumor lysis syndrome
Chapter 35 tumor lysis syndromeChapter 35 tumor lysis syndrome
Chapter 35 tumor lysis syndrome
 
Chapter 34 medical stat
Chapter 34 medical statChapter 34 medical stat
Chapter 34 medical stat
 
Chapter 33 isolated tumor cells
Chapter 33 isolated tumor cellsChapter 33 isolated tumor cells
Chapter 33 isolated tumor cells
 
Chapter 32 invasion and metastasis
Chapter 32 invasion and metastasisChapter 32 invasion and metastasis
Chapter 32 invasion and metastasis
 
Chapter 31 genetic counselling
Chapter 31 genetic counsellingChapter 31 genetic counselling
Chapter 31 genetic counselling
 
Chapter 30 febrile neutropenia
Chapter 30 febrile neutropeniaChapter 30 febrile neutropenia
Chapter 30 febrile neutropenia
 
Chapter 29 dendritic cells
Chapter 29 dendritic cellsChapter 29 dendritic cells
Chapter 29 dendritic cells
 
Chapter 28 clincal trials
Chapter 28 clincal trials Chapter 28 clincal trials
Chapter 28 clincal trials
 
Chapter 27 chemotherapy side effects dr lms
Chapter 27 chemotherapy side effects  dr lmsChapter 27 chemotherapy side effects  dr lms
Chapter 27 chemotherapy side effects dr lms
 
Chapter 26 chemoprevention of cancer
Chapter 26 chemoprevention of cancerChapter 26 chemoprevention of cancer
Chapter 26 chemoprevention of cancer
 
Chapter 25 assessment of clincal responses
Chapter 25 assessment of clincal responsesChapter 25 assessment of clincal responses
Chapter 25 assessment of clincal responses
 
Chapter 24.3 metronomic chemotherapy
Chapter 24.3 metronomic chemotherapyChapter 24.3 metronomic chemotherapy
Chapter 24.3 metronomic chemotherapy
 
Chapter 24.2 lmwh in cancer asso thrombosis
Chapter 24.2 lmwh in cancer asso thrombosisChapter 24.2 lmwh in cancer asso thrombosis
Chapter 24.2 lmwh in cancer asso thrombosis
 
Chapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodiesChapter 24.1 kinase inhibitors and monoclonal antibodies
Chapter 24.1 kinase inhibitors and monoclonal antibodies
 
Chapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitorsChapter 24 tyrosine kinase inhibitors
Chapter 24 tyrosine kinase inhibitors
 

Recently uploaded

BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptxBOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
AnushriSrivastav
 
VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...
VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...
VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...
Nguyễn Thị Vân Anh
 
Roti bank chennai PPT [Autosaved].pptx1
Roti bank  chennai PPT [Autosaved].pptx1Roti bank  chennai PPT [Autosaved].pptx1
Roti bank chennai PPT [Autosaved].pptx1
roti bank
 
CANCER CANCER CANCER CANCER CANCER CANCER
CANCER  CANCER  CANCER  CANCER  CANCER CANCERCANCER  CANCER  CANCER  CANCER  CANCER CANCER
CANCER CANCER CANCER CANCER CANCER CANCER
KRISTELLEGAMBOA2
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
AnushriSrivastav
 
Myopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptxMyopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptx
RitonDeb1
 
VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...
VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...
VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...
rajkumar669520
 
Navigating the Health Insurance Market_ Understanding Trends and Options.pdf
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfNavigating the Health Insurance Market_ Understanding Trends and Options.pdf
Navigating the Health Insurance Market_ Understanding Trends and Options.pdf
Enterprise Wired
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
Naeemshahzad51
 
Immunity to Veterinary parasitic infections power point presentation
Immunity to Veterinary parasitic infections power point presentationImmunity to Veterinary parasitic infections power point presentation
Immunity to Veterinary parasitic infections power point presentation
BeshedaWedajo
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
The Harvest Clinic
 
HEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptxHEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptx
priyabhojwani1200
 
the IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meetingthe IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meeting
ssuser787e5c1
 
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
ranishasharma67
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
TheDocs
 
Navigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and BeyondNavigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and Beyond
Aboud Health Group
 
A Community health , health for prisoners
A Community health  , health for prisonersA Community health  , health for prisoners
A Community health , health for prisoners
Ahmed Elmi
 
Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.
Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.
Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.
preciousstephanie75
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Dr. David Greene Arizona
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Rommel Luis III Israel
 

Recently uploaded (20)

BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptxBOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
 
VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...
VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...
VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...
 
Roti bank chennai PPT [Autosaved].pptx1
Roti bank  chennai PPT [Autosaved].pptx1Roti bank  chennai PPT [Autosaved].pptx1
Roti bank chennai PPT [Autosaved].pptx1
 
CANCER CANCER CANCER CANCER CANCER CANCER
CANCER  CANCER  CANCER  CANCER  CANCER CANCERCANCER  CANCER  CANCER  CANCER  CANCER CANCER
CANCER CANCER CANCER CANCER CANCER CANCER
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
 
Myopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptxMyopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptx
 
VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...
VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...
VVIP Dehradun Girls 9719300533 Heat-bake { Dehradun } Genteel ℂall Serviℂe By...
 
Navigating the Health Insurance Market_ Understanding Trends and Options.pdf
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfNavigating the Health Insurance Market_ Understanding Trends and Options.pdf
Navigating the Health Insurance Market_ Understanding Trends and Options.pdf
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
 
Immunity to Veterinary parasitic infections power point presentation
Immunity to Veterinary parasitic infections power point presentationImmunity to Veterinary parasitic infections power point presentation
Immunity to Veterinary parasitic infections power point presentation
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
 
HEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptxHEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptx
 
the IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meetingthe IUA Administrative Board and General Assembly meeting
the IUA Administrative Board and General Assembly meeting
 
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
Haridwar ❤CALL Girls 🔝 89011★83002 🔝 ❤ℂall Girls IN Haridwar ESCORT SERVICE❤
 
The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........The Docs PPG - 30.05.2024.pptx..........
The Docs PPG - 30.05.2024.pptx..........
 
Navigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and BeyondNavigating Women's Health: Understanding Prenatal Care and Beyond
Navigating Women's Health: Understanding Prenatal Care and Beyond
 
A Community health , health for prisoners
A Community health  , health for prisonersA Community health  , health for prisoners
A Community health , health for prisoners
 
Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.
Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.
Surgery-Mini-OSCE-All-Past-Years-Questions-Modified.
 
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
 

Chapter 37 svco

  • 1.
  • 2.  Superior vena cava (SVC) syndrome results from any condition that leads to obstruction of blood flow through the SVC.  Obstruction can be caused by invasion or external compression of the superior vena cava by adjacent pathologic processes involving the right lung, lymph nodes, and other mediastinal structures, or by thrombosis of blood within the SVC.  In some cases, both external compression and thrombosis coexist
  • 3.  In the preantibiotic era, syphilitic thoracic aortic aneurysms, fibrosing mediastinitis, and other complications of untreated infection were frequent causes of the SVC syndrome.  In the postantibiotic era, malignancy became the most common cause.  More recently, the incidence of SVC syndrome due to thrombosis has risen, largely because of increased use of intravascular devices such as catheters and pacemaker wires.
  • 4. PATHOPHYSIOLOGY —  Obstruction of the SVC can be caused by invasion or external compression by adjacent pathologic processes involving the right lung, lymph nodes, or other mediastinal structures, or by thrombosis of blood within the SVC.  As the flow of blood within the SVC becomes obstructed, venous collaterals form, establishing alternative pathways for the return of venous blood to the right atrium.
  • 5.  Collateral veins may arise from the azygos, internal mammary, lateral thoracic, paraspinous, and esophageal venous systems.  The venous collaterals dilate over several weeks.  As a result, upper body venous pressure is markedly elevated initially but decreases over time.  However, even when well-developed collateral drainage patterns are present, central venous pressures remain elevated, producing the characteristic signs and symptoms of SVC syndrome.
  • 6.  The rapidity of onset of symptoms and signs from SVC obstruction depends upon the rate at which complete obstruction of the SVC occurs in relation to the recruitment of venous collaterals.  Patients with malignant disease may develop symptoms of SVC syndrome within weeks to months because rapid tumor growth does not allow adequate time to develop collateral flow.
  • 7.  The interstitial edema of the head and neck is visually striking but generally of little clinical consequence.  However, edema may narrow the lumen of the nasal passages and larynx, potentially compromising the function of the larynx or pharynx and causing dyspnea, stridor, cough, hoarseness, and dysphagia.  In addition, cerebral edema can also occur and lead to cerebral ischemia, herniation, and possibly death.  Cardiac output may be diminished transiently by acute SVC obstruction, but within a few hours, blood return is reestablished by increased venous pressure and collaterals.
  • 8.  Hemodynamic compromise, if present, more often results from mass effect on the heart than from SVC compression
  • 9.  Etiology :  Malignancy —  An intrathoracic malignancy is responsible for 60 to 85 percent of cases of SVC syndrome.  Non-small cell lung cancer (NSCLC) is the most common malignant cause of SVC syndrome, accounting for 50 percent of all cases , followed by small cell lung cancer (SCLC, 25 percent of all cases) and non- Hodgkin lymphoma (NHL, 10 percent of cases).  Together, lung cancer and NHL are responsible for approximately 95 percent of cases of SVC syndrome that are caused by malignancy .
  • 10.  Lung cancer —  Approximately 2 to 4 percent of patients with lung cancer develop SVC syndrome at some point during their disease course .  SVC syndrome is more common with SCLC, occurring in approximately 10 percent of cases at presentation.  This is presumably because SCLC develops and grows rapidly in central rather than peripheral airways.  Fewer than 2 percent of patients presenting with NSCLC have SVC syndrome as a complication, but because of the higher incidence, NSCLC is a more frequent cause of SVC syndrome than is SCLC .  Venous obstruction in these cases results from extrinsic compression of the SVC by either the primary tumor or enlarged mediastinal lymph nodes, or as a result of direct tumor invasion of the SVC .
  • 11.  Lymphoma —  SVC syndrome develops in 2 to 4 percent of cases of NHL.  Diffuse large cell and lymphoblastic lymphomas are the most common subtypes that are associated with SVC syndrome.  SVC syndrome is even more common in patients with primary mediastinal large B- cell lymphoma with sclerosis, an unusual and aggressive NHL subtype that represents 3 to 7 percent of all diffuse large-cell lymphomas.  Patients typically present with a rapidly enlarging anterior mediastinal mass, frequently with associated SVC syndrome.
  • 12.  Although most NHLs cause SVC syndrome by extrinsic compression due to enlarged lymph nodes , patients with intravascular (angiotropic) lymphoma have intravascular occlusion as the primary pathogenic mechanism .  Other — Other malignant tumors that are less commonly associated with the SVC syndrome include : thymoma, primary mediastinal germ cell neoplasms, mesothelioma, and solid tumors with mediastinal lymph node metastases (eg, breast cancer)
  • 13.  Nonmalignant disorders —  Nonmalignant conditions account for 15 to 40 percent of SVC obstructions.  Although the incidence of SVC syndrome due to infections such as tuberculosis and syphilis has decreased, there has been an increase in SVC thrombosis associated with the presence of intravascular devices such as central venous catheters and cardiac pacemaker leads
  • 14.  Clinical maniestations:  Regardless of etiology, dyspnea is the most common symptom .  In addition, patients frequently complain of facial swelling or head fullness, which may be exacerbated by bending forward or lying down.  Other symptoms include arm swelling, cough, chest pain, or dysphagia.  Patients with cerebral edema may have headaches, confusion, or possibly coma.
  • 15.  On physical examination, the most common findings are facial edema and venous distension in the neck and on the chest wall .  Arm edema, cyanosis, and facial plethora can be seen.  In most cases, symptoms are gradually progressive over several weeks and then get better over time, due to the development of venous collaterals.